RESUMO
Rabies virus (RABV) causes a severe and fatal neurological disease, but morbidity is vaccine preventable and treatable prior to the onset of clinical symptoms. However, immunoglobulin (IgG)-based rabies postexposure prophylaxis (PEP) is expensive, restricting access to life-saving treatment, especially for patients in low-income countries where the clinical need is greatest, and does not confer cross-protection against newly emerging phylogroup II lyssaviruses. Toward identifying a cost-effective replacement for the IgG component of rabies PEP, we developed and implemented a high-throughput screening protocol utilizing a single-cycle RABV reporter strain. A large-scale screen and subsequent direct and orthogonal counterscreens identified a first-in-class direct-acting RABV inhibitor, GRP-60367, with a specificity index (SI) of >100,000. Mechanistic characterization through time-of-addition studies, transient cell-to-cell fusion assays, and chimeric vesicular stomatitis virus (VSV) recombinants expressing the RABV glycoprotein (G) demonstrated that GRP-60367 inhibits entry of a subset of RABV strains. Resistance profiling of the chemotype revealed hot spots in conserved hydrophobic positions of the RABV G protein fusion loop that were confirmed in transient cell-to-cell fusion assays. Transfer of RABV G genes with signature resistance mutations into a recombinant VSV backbone resulted in the recovery of replication-competent virions with low susceptibility to the inhibitor. This work outlines a tangible strategy for mechanistic characterization and resistance profiling of RABV drug candidates and identified a novel, well-behaved molecular probe chemotype that specifically targets the RABV G protein and prevents G-mediated viral entry.IMPORTANCE Rabies PEP depends on anti-RABV IgG, which is expensive and in limited supply in geographical areas with the highest disease burden. Replacing the IgG component with a cost-effective and shelf-stable small-molecule antiviral could address this unmet clinical need by expanding access to life-saving medication. This study has established a robust protocol for high-throughput anti-RABV drug screens and identified a chemically well-behaved, first-in-class hit with nanomolar anti-RABV potency that blocks RABV G protein-mediated viral entry. Resistance mapping revealed a druggable site formed by the G protein fusion loops that has not previously emerged as a target for neutralizing antibodies. Discovery of this RABV entry inhibitor establishes a new molecular probe to advance further mechanistic and structural characterization of RABV G that may aid in the design of a next-generation clinical candidate against RABV.
Assuntos
Anticorpos Neutralizantes/uso terapêutico , Avaliação Pré-Clínica de Medicamentos/métodos , Vírus da Raiva/imunologia , Animais , Anticorpos Antivirais/imunologia , Antivirais/farmacologia , Linhagem Celular , Proteção Cruzada , Humanos , Biblioteca de Peptídeos , Raiva/prevenção & controle , Vacina Antirrábica/imunologia , Vírus da Raiva/metabolismo , Vírus da Raiva/patogenicidade , Vírus da Estomatite Vesicular Indiana/genética , Vírus da Estomatite Vesicular Indiana/imunologia , Vesiculovirus/genética , Vesiculovirus/imunologia , Proteínas Virais de Fusão/farmacologiaRESUMO
Semliki Forest virus (SFV), a neurotropic virus, has been used to deliver heterologous genes into cells in vitro and in vivo. In this study, we constructed a reporter SFV4-FL-EGFP and found that it can deliver EGFP into neurons located at the injection site without disseminating throughout the brain. Lacking of the capsid gene of SFV4-FL-EGFP does not block its life cycle, while forming replication-competent virus-like particles (VLPs). These VLPs hold subviral genome by using the packaging sequence (PS) located within the nsP2 gene, and can transfer their genome into cells. In addition, we found that the G protein of vesicular stomatitis virus (VSVG) can package SFV subviral genome, which is consistent with the previous reports. The G protein of rabies virus (RVG) could also package SFV subviral genome. These pseudo-typed SFV can deliver EGFP gene into neurons. Taken together, these findings may be used to construct various SFV-based delivery systems for virological studies, gene therapy, and neural circuit labeling.
Assuntos
Engenharia Genética , Terapia Genética/métodos , Vetores Genéticos/metabolismo , Hipotálamo/virologia , Neurônios/virologia , Vírus da Floresta de Semliki/genética , Animais , Linhagem Celular , Cricetulus , Células Epiteliais/ultraestrutura , Células Epiteliais/virologia , Expressão Gênica , Genes Reporter , Vetores Genéticos/química , Proteínas de Fluorescência Verde/genética , Proteínas de Fluorescência Verde/metabolismo , Hipotálamo/ultraestrutura , Injeções Intraventriculares , Glicoproteínas de Membrana/genética , Glicoproteínas de Membrana/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Neurônios/ultraestrutura , Cultura Primária de Células , Vírus da Raiva/genética , Vírus da Raiva/metabolismo , Vírus da Floresta de Semliki/metabolismo , Vesiculovirus/genética , Vesiculovirus/metabolismo , Proteínas do Envelope Viral/genética , Proteínas do Envelope Viral/metabolismo , Vírion/genética , Vírion/metabolismo , Montagem de Vírus/genéticaRESUMO
The recombinant G glycoprotein from the surface of the rabies virus (RVGP) is a promising candidate as a rabies vaccine component and also for diagnostic purposes. In this study, RVGP production by transfected Drosophila melanogaster S2 cells cultivated in a serum-free medium (supplemented IPL-41 medium) was carried out. The effects of pH and pO(2) were evaluated in batch culture in parallel spinner flasks. The use of a pH equal to 6.3 and a pO(2) of 40% air saturation resulted in the highest RVGP content. These conditions were also used in fed-batch mode, yielding a RVGP content level of 98g/10(7) cells. The main nutrients consumed were glucose, glutamine, asparagine, serine and proline and the major metabolites produced were alanine and ammonia, according to the metabolism studies performed. Since RVGP is a transmembrane protein, two different methods for protein recovery were assessed and compared. Detergent-based cell disruption showed to be more effective than mechanical disruption with glass beads for glycoprotein recovery.
Assuntos
Linhagem Celular , Meios de Cultura Livres de Soro/farmacologia , Drosophila melanogaster , Proteínas Recombinantes/metabolismo , Proteínas Virais de Fusão/isolamento & purificação , Proteínas Virais de Fusão/metabolismo , Aminoácidos/metabolismo , Animais , Metabolismo dos Carboidratos/efeitos dos fármacos , Técnicas de Cultura de Células , Linhagem Celular/metabolismo , Linhagem Celular/fisiologia , Proliferação de Células/efeitos dos fármacos , Concentração de Íons de Hidrogênio , Ácido Láctico/metabolismo , Consumo de Oxigênio/efeitos dos fármacos , Vírus da Raiva/genética , Vírus da Raiva/metabolismo , Proteínas Recombinantes/genética , Fatores de TempoRESUMO
The fatty acylation of rabies virus (CVS strain) proteins was investigated. [3H]palmitic acid was found to be incorporated into the glycoprotein G and to a lesser extent into the membrane-associated protein M2. The fatty acid linkage on G was sensitive to sodium borohydride, mercaptoethanol, and hydroxylamine, indicating that the linkage was of the thiolester type. Bromelain digestion indicated that the palmitoylation site on G was located in the intracytoplasmic domain or in the transmembrane domain in which there is only one cysteine in position 461. Therefore, palmitoylation is likely to occur at this position. In the case of M2, the linkage was also sensitive to hydroxylamine and sodium borohydride and to a lesser extent to mercaptoethanol, suggesting that the linkage also occurred on a cysteine.